International PPB/DICER1 Registry
Public ClinicalTrials.gov record NCT03382158. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
International Pleuropulmonary Blastoma/DICER1 Registry (for PPB, DICER1 and Associated Conditions)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a partially cystic, partially solid tumor, Type III is a completely solid tumor. Treatment of children with PPB is at the discretion of the treating institution. This study builds off of the 2009 study and will also seek to enroll individuals with DICER1-associated conditions, some of whom may present only with the DICER1 gene mutation, which will help the Registry understand how these tumors and conditions develop, their clinical course and the most effective treatments.
Study identification
- NCT ID
- NCT03382158
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 3,400 participants
Conditions and interventions
Conditions
- Pleuropulmonary Blastoma
- Sertoli-Leydig Cell Tumor
- DICER1 Syndrome
- Cystic Nephroma
- Wilms Tumor
- Pineoblastoma
- Renal Sarcoma
- Nodular Hyperplasia of Thyroid
- Nasal Chondromesenchymal Hamartoma
- Ciliary Body Medulloepithelioma
- Neuroblastoma
- Pituitary Cancer
- Embryonal Rhabdomyosarcoma
- Ovarian Sarcoma
- Gynandroblastoma
- Thyroid Carcinoma
- Embryonal Rhabdomyosarcoma of Vagina (Diagnosis)
- Embryonal Rhabdomyosarcoma of Uterus (Diagnosis)
- Embryonal Rhabdomyosarcoma of Cervix
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 0 Minutes to 100 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 5, 2016
- Primary completion
- Dec 5, 2030
- Completion
- Dec 5, 2035
- Last update posted
- Jan 29, 2025
2016 – 2035
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Minnesota | Minneapolis | Minnesota | 55404 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03382158, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03382158 live on ClinicalTrials.gov.